Musculoskeletal Biology, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Department of Epidemiology and Biostatistics, School of Public Health, Zhejiang Chinese Medical University, Zhejiang, 310053, Hangzhou, China.
Clin Rheumatol. 2021 Sep;40(9):3729-3733. doi: 10.1007/s10067-021-05718-3. Epub 2021 Mar 30.
Clinicians are advised caution in reducing serum urate for gout management due to observational associations with risk of neuropsychiatric diseases. We examined the causal effect of genetically predicted serum urate levels on the risk of major depressive disorder (MDD), anxiety, and related psychiatric disorders using two-sample Mendelian randomization (MR). We identified single-nucleotide polymorphisms (SNPs) associated with serum urate from a genome-wide association study (GWAS) of 110,347 European-descent individuals. The causal effect of serum urate on MDD was tested using summary data from a GWAS of 135,458 cases and 344,901 controls of European descent. MR was performed using random-effects inverse variance-weighted method and a series of sensitivity analyses. This approach was repeated using summary GWAS data for anxiety, bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, schizophrenia, and anorexia nervosa. We identified 30 SNPs associated with serum urate. Genetically predicted urate levels were not causally associated with risk of MDD (OR 0.98; 95% CI 0.94, 1.03), anxiety (OR 0.90; 95% CI 0.80, 1.02), or the other psychiatric conditions (OR range 0.95 to 1.06). Results were similar in sensitivity analyses. We found no evidence that genetically predicted serum urate has a causal effect on risk of MDD, anxiety, or other psychiatric disorders. Key Points • Clinicians are advised to be cautious about reducing the serum urate level too far in gout management, citing observational associations between low serum urate levels and various neuropsychiatric diseases. • In this two-sample Mendelian randomization study, we found no evidence for a causal link between genetically predicted serum urate level and the development of major depressive, anxiety, or other related psychiatric disorders. • Future revisions of clinical guidelines may need to reconsider recommendations regarding lower limits for serum urate levels.
临床医生在进行痛风管理以降低血尿酸时应谨慎,因为观察到血尿酸水平降低与多种神经精神疾病有关。我们使用两样本 Mendelian 随机化 (MR) 方法,检查了遗传预测的血清尿酸水平与重度抑郁症 (MDD)、焦虑症和相关精神疾病风险之间的因果关系。我们从一项包含 110347 名欧洲血统个体的全基因组关联研究 (GWAS) 中确定了与血清尿酸相关的单核苷酸多态性 (SNP)。使用欧洲血统的 135458 例病例和 344901 例对照的 GWAS 汇总数据测试了血清尿酸对 MDD 的因果影响。MR 使用随机效应逆方差加权法和一系列敏感性分析进行。使用焦虑症、双相情感障碍、创伤后应激障碍、强迫症、注意缺陷多动障碍、精神分裂症和神经性厌食症的汇总 GWAS 数据重复了这种方法。我们确定了 30 个与血清尿酸相关的 SNP。遗传预测的尿酸水平与 MDD 风险无因果关系 (OR 0.98;95%CI 0.94,1.03)、焦虑症 (OR 0.90;95%CI 0.80,1.02) 或其他精神疾病 (OR 范围 0.95 至 1.06)。敏感性分析结果相似。我们没有发现遗传预测的血清尿酸对 MDD、焦虑症或其他精神疾病风险有因果影响的证据。 要点 • 临床医生在痛风管理中建议谨慎降低血清尿酸水平,因为低血清尿酸水平与各种神经精神疾病有关。 • 在这项两样本 Mendelian 随机化研究中,我们没有发现遗传预测的血清尿酸水平与重度抑郁、焦虑或其他相关精神疾病的发展之间存在因果关系。 • 临床指南的未来修订可能需要重新考虑血清尿酸水平下限的建议。